Deutsches Krebsforschungszentrum

Fidia Farmaceutici S.p.a.

Deutsche Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Landesstiftung Baden-wurttemberg Ggmbh

Gkss-forschungszentrum Geesthacht Gmbh

Helmholtz-zentrum Geesthacht Zentrum Fur Material Und Kustenforschung Gmbh

Baden-wurttemberg Stiftung Ggmbh

Norbert Fusenig

Andreas Lendlein

Alessandra Pavesio

Peter Angel

Sven Andrecht

Axel Szabowski

Marina Schorpp-Kistner

Hans-Jürgen Stark

Wolfgang Thon

Nicole Maas-Szabowski

Andrea Kolbus

Thomas Groth

Michael Willhauck

Karsten Boehnke

Petra Boukamp

Hans-Juergen Stark

Karsten BÖHNKE

Gregor Boese

Günther Malsch

The present invention relates to organotypic cultures of epidermal cells and the use thereof for the screening of pharmaceutical and cosmetic agents. Specifically, means for the improvement of the long-term stability of such cultures are disclosed. Thus, the present invention contemplates a skin equivalent comprising (a) a dermal equivalent comprising a matrix comprising nonwoven viscose fabric and fibroblasts and (b) keratinocytes. Moreover, the present invention contemplates a method for manufacturing the skin equivalent and a method for screening agents capable of influencing skin, such as a therapeutic or cosmetic agent.

Scaffold-based organotypic culture for the long-term cultivation of human epidermal stem cells

The use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association with natural, synthetic or semisynthetic biopolymers, for suppressing the angiogenic process associated with tumor proliferation (in primary and secondary tumors) is disclosed.

Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumors

The invention relates to genetically modified fibroblast cells which comprise the following properties: (a) a gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor of the signal transduction pathway is modified resulting in a modified AP-1 activity; (b) functionally linked with a promoter, it contains in an expression vector the gene from (a) in a form such that the active subunit is only expressed after induction of the promoter or the subunit encoded by the gene is present in inactive form and a form that can be activated. Furthermore, the invention relates to a method which uses the fibroblast cell according to the invention to identify a compound which can support, inhibit or modify the AP-1-dependent differentiation and/or proliferation of keratinocytes or a gene which is involved in the AP-1-dependent differentiation and/or proliferation of keratinocytes as well as to the use of the test compound identified according to the method of the invention and the gene for treating or diagnosing diseases associated with a disturbed proliferation and/or differentiation of keratinocytes.

Genetically modified fibroblast cells

A petri dish has on its bottom a plurality of zones surrounded by elevated ridges spatially separating the zones from one another.

Petri dish

Growing community of inventors

Heidelberg, Germany

Norbert Fusenig